Control of meningococcal meningitis with meningococcal vaccines.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Artenstein MS
  • Source:
    The Yale journal of biology and medicine [Yale J Biol Med] 1975 Jul; Vol. 48 (3), pp. 197-200.
  • Publication Type:
    Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Yale Journal of Biology and Medicine Country of Publication: United States NLM ID: 0417414 Publication Model: Print Cited Medium: Print ISSN: 0044-0086 (Print) Linking ISSN: 00440086 NLM ISO Abbreviation: Yale J Biol Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: New Haven, CT : Yale Journal of Biology and Medicine
    • Subject Terms:
      Vaccination*; Meningitis, Meningococcal/*prevention & control ; Vaccines/*standards; Adult ; Antibodies, Bacterial/analysis ; Antibody Formation ; Antibody Specificity ; Antigens, Bacterial/analysis ; Blood Bactericidal Activity ; Humans ; Immunity ; Infant ; Male ; Meningitis, Meningococcal/immunology ; Military Medicine ; Neisseria meningitidis/immunology ; Neisseria meningitidis/isolation & purification ; United States
    • Abstract:
      The development of effective meinigococcal vaccines was based upon the finding that immunity to the meningococcus was directly correlated with serum bactericidal antibodies. Purified high molecular weight capsular polysaccharides of serogroups A and C meningococci stimulated the production of humoral antibodies which had group specific bactericidal activity. In controlled field trials in Army recruits, group C polysaccharide vaccines were highly effective in preventing group C disease. Following its use as a routine immunization in recruits in October 1971 group C meningococcal disease has been almost completely eliminated from Army training centers. Group A vaccine has been field tested in Egyptian school children with great success. Group B polysaccharide has failed to induce bactericidal antibodies in humans and, therefore, new research is underway to attempt to develop a cell wall protein antigen as a vaccine against group B disease.
    • Number of References:
      16
    • References:
      J Infect Dis. 1974 Sep;130(3):240-7. (PMID: 4213017)
      Bull World Health Organ. 1973 Jun;48(6):667-73. (PMID: 4206451)
      J Infect Dis. 1972 Nov;126(5):514-21. (PMID: 4197754)
      J Exp Med. 1969 Jun 1;129(6):1349-65. (PMID: 4977282)
      J Exp Med. 1969 Jun 1;129(6):1367-84. (PMID: 4977283)
      N Engl J Med. 1970 Feb 19;282(8):417-20. (PMID: 4983754)
      Infect Immun. 1974 Nov;10(5):975-84. (PMID: 16558113)
      JAMA. 1963 Oct 12;186:139-41. (PMID: 14056528)
      Mil Med. 1970 Sep;135(9):735-9. (PMID: 4991223)
      J Infect Dis. 1970 Apr;121(4):372-7. (PMID: 4985950)
      Infect Immun. 1972 Nov;6(5):835-51. (PMID: 4629210)
      J Exp Med. 1969 Jun 1;129(6):1307-26. (PMID: 4977280)
    • Accession Number:
      0 (Antibodies, Bacterial)
      0 (Antigens, Bacterial)
      0 (Vaccines)
    • Publication Date:
      Date Created: 19750701 Date Completed: 19751122 Latest Revision: 20181113
    • Publication Date:
      20231215
    • Accession Number:
      PMC2595232
    • Accession Number:
      808913